Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition.
Szczepanski T, van der Velden VH, Waanders E, Kuiper RP, Van Vlierberghe P, Gruhn B, Eckert C, Panzer-Grümayer R, Basso G, Cavé H, Stadt UZ, Campana D, Schrauder A, Sutton R, van Wering E, Meijerink JP, van Dongen JJ. Szczepanski T, et al. Among authors: van der velden vh, van dongen jj, van wering e, van vlierberghe p. J Clin Oncol. 2011 Apr 20;29(12):1643-9. doi: 10.1200/JCO.2010.30.2877. Epub 2011 Feb 28. J Clin Oncol. 2011. PMID: 21357790
Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma.
Provez L, Putteman T, Landfors M, Roels J, Reunes L, T'Sas S, Van Loocke W, Lintermans B, De Coninck S, Thenoz M, Sleeckx W, Maćkowska-Maślak N, Taghon T, Mansour MR, Farah N, Norga K, Vandenberghe P, Kotecha RS, Goossens S, Degerman S, De Smedt R, Van Vlierberghe P. Provez L, et al. Among authors: van vlierberghe p. Cancers (Basel). 2023 Jan 20;15(3):647. doi: 10.3390/cancers15030647. Cancers (Basel). 2023. PMID: 36765607 Free PMC article.
CircFBXW7 in patients with T-cell ALL: depletion sustains MYC and NOTCH activation and leukemia cell viability.
Buratin A, Borin C, Tretti Parenzan C, Dal Molin A, Orsi S, Binatti A, Simon K, Paganin M, Serafin V, Gaffo E, Te Kronnie G, Van Vlierberghe P, Bresolin S, Bortoluzzi S. Buratin A, et al. Among authors: van vlierberghe p. Exp Hematol Oncol. 2023 Jan 21;12(1):12. doi: 10.1186/s40164-023-00374-6. Exp Hematol Oncol. 2023. PMID: 36681829 Free PMC article.
The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia.
Van Vlierberghe P, van Grotel M, Beverloo HB, Lee C, Helgason T, Buijs-Gladdines J, Passier M, van Wering ER, Veerman AJ, Kamps WA, Meijerink JP, Pieters R. Van Vlierberghe P, et al. Among authors: van grotel m, van wering er. Blood. 2006 Nov 15;108(10):3520-9. doi: 10.1182/blood-2006-04-019927. Epub 2006 Jul 27. Blood. 2006. PMID: 16873670 Free article.
Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.
Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, Mentens N, Beverloo HB, Pieters R, Speleman F, Odero MD, Bauters M, Froyen G, Marynen P, Vandenberghe P, Wlodarska I, Meijerink JP, Cools J. Lahortiga I, et al. Among authors: van vlierberghe p. Nat Genet. 2007 May;39(5):593-5. doi: 10.1038/ng2025. Epub 2007 Apr 15. Nat Genet. 2007. PMID: 17435759
Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis.
Balgobind BV, Van Vlierberghe P, van den Ouweland AM, Beverloo HB, Terlouw-Kromosoeto JN, van Wering ER, Reinhardt D, Horstmann M, Kaspers GJ, Pieters R, Zwaan CM, Van den Heuvel-Eibrink MM, Meijerink JP. Balgobind BV, et al. Among authors: van den heuvel eibrink mm, van den ouweland am, van wering er, van vlierberghe p. Blood. 2008 Apr 15;111(8):4322-8. doi: 10.1182/blood-2007-06-095075. Epub 2008 Jan 2. Blood. 2008. PMID: 18172006 Free article.
144 results